Novozymes accelerates growth in Q3 and is on track to deliver on full-year expectations

Share This Article

After three-quarters of the 2023 financial year, Novozymes sees increasing demand for sustainable biosolutions and delivers 5% organic sales growth. The company’s full-year organic sales growth outlook is maintained at 4-6%. During the first nine months of the 2023 financial year, Novozymes launched 10 new products, four of which were public. Novozyme is close to the completion of its combination with Chr. Hansen, expected to be completed in the fourth quarter of 2023 or the first quarter of 2024. In the third quarter, China, Brazil, and Turkey joined the countries granting regulatory approval regarding the combination with Chr. Hansen. South Korea and EU clearance is outstanding. 

Source :- Link